Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: OTC US
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Neurobiological Technologies Inc

+ Add to Watchlist

NTII:US

0.0200 USD 0.0050 20.00%

As of 20:10:00 ET on 05/22/2015.

Snapshot for Neurobiological Technologies Inc (NTII)

Open: 0.0200 Day's Range: 0.0200 - 0.0200 Volume: 10,000
Previous Close: 0.0250 52wk Range: 0.0150 - 0.0500 1-Yr Rtn: -59.18%

Stock Chart for NTII

No chart data available.
  • NTII:US 0.0200
  • 1D
  • 1M
  • 1Y
0.0250
Interactive NTII Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for NTII

Current P/E Ratio (ttm) 0.0270
Estimated P/E(06/2010) -
Relative P/E vs. SPX 0.0014
Earnings Per Share (USD) (ttm) 0.7400
Est. EPS (USD) (06/2010) -
Est. PEG Ratio -
Market Cap (M USD) 0.54
Shares Outstanding (M) 27.02
30 Day Average Volume 44,400
Price/Book (mrq) 0.0232
Price/Sale (ttm) 0.0213
Dividend Indicated Gross Yield -%
Cash Dividend (USD) 0.0500
Dividend Ex-Date 12/18/2012
5 Year Dividend Growth -
Next Earnings Announcement -
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for NTII

No data available

Company Profile & Key Executives for NTII

Neurobiological Technologies, Inc. (NTI) is a biopharmaceutical company focused on the clinical development and regulatory approval of neuroscience drugs. NTI is developing neuroprotective and neuromodulatory agents to treat progressive neurological impairments characteristic of various nervous system disorders, including diabetic neuropathy, brain cancer, and AIDS dementia syndrome.

Matthew M LoarActing CEO/Acting CFO
More Company Profile & Key Executives for NTII

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil